共 50 条
- [31] Design and discovery of MRTX0902, a potent, selective, and orally bioavailable SOS1 inhibitor.CANCER RESEARCH, 2022, 82 (12)Ketcham, John M.Briere, David M.Burns, Aaron C.Christensen, James G.Gunn, Robin J.Haling, JacobIvetac, AnthonyKhare, ShilpiKuehler, JonKulyk, SvitlanaLaguer, JadeLawson, John D.Moya, KrystalNguyen, NatalieOlson, PeterRahbaek, LisaSmith, Christopher R.Sudhakar, NiranjanThomas, Nicole C.Vanderpool, DarinWang, XiaolunMarx, Matthew A.
- [32] Potent antitumor activity of MLN0128, an investigational selective mTORC1/2 kinase inhibitor, in preclinical models of rhabdomyosarcomaCANCER RESEARCH, 2014, 74 (19)Slotkin, EmilyPatwardhan, ParagDeraje, Shyamprasad VasudevaSchwartz, GaryWilliam, Tap
- [33] Design, Synthesis, and Biological Evaluation of an Orally Bioavailable, Potent, and Selective ROCK2 Inhibitor for Psoriasis TreatmentJOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (22) : 15205 - 15229Huang, YunMao, Chu-RuLou, YijieZhan, ShuaiChen, ZheDing, WanjingMa, Zhongjun
- [34] Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor VenetoclaxBLOOD, 2016, 128 (22)Tarantelli, ChiaraGaudio, EugenioHillmann, PetraSpriano, FilippoKwee, IvoRinaldi, AndreaStathis, AnastasiosZucca, EmanueleFabbro, DorianoCmiljanovic, VladimirBertoni, Francesco
- [35] Discovery of OSI-027: An imidazotriazine-based orally efficacious dual inhibitor of mTORC1 and mTORC2ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243Dong, HanqingBhagwat, Shripad V.Beard, DavidBharadwaj, ApoorbaBittner, Mark A.Chen, XinCoate, HeatherCooke, AndrewGokhale, PrafullaKahler, JenniferMantis, ChristineMulvihill, Mark J.Panicker, BijoyTavares-Greco, Paula A.Volk, BrianWang, JingWerner, Douglas S.Yao, YanArnold, Lee D.Pachter, Jonathan A.Wild, RobertEpstein, DavidCrew, Andrew P.
- [36] Pharmacological effects of mTORC1/C2 inhibitor in a preclinical model of NASH progressionBIOMEDICINE & PHARMACOTHERAPY, 2023, 167Arora, MahakPavlikova, ZuzanaKucera, TomasKozlik, PetrSopin, TijanaVacik, TomasL'uptak, MatejDuda, MatthiasSlanar, OndrejCanova, Nikolina Kutinov
- [37] Discovery of a Potent, Selective, and Orally Bioavailable Pyridinyl-Pyrimidine Phthalazine Aurora Kinase InhibitorJOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (17) : 6368 - 6377Cee, Victor J.Schenkel, Laurie B.Hodous, Brian L.Deak, Holly L.Nguyen, Hanh N.Olivieri, Philip R.Romero, KarinaBak, AnnetteBe, XuhaiBellon, SteveBush, Tammy L.Cheng, Alan C.Chung, GraceCoats, SteveEden, Patrick M.Hanestad, KellyGallant, Paul L.Gu, YanHuang, XinKendall, Richard L.Lin, Min-Hwa JasmineMorrison, Michael J.Patel, Vinod F.Radinsky, RobertRose, Paul E.Ross, SandraSun, Ji-RongTang, JinZhao, HuilinPayton, MarcGeuns-Meyer, Stephanie D.
- [38] Discovery of WX486 as a novel, potent, selective, and orally bioavailable irreversible inhibitor of BTKJOURNAL OF IMMUNOLOGY, 2016, 196Wu, ChengdeShen, ChunliZhu, YuchuanHu, GuopingLin, JianChen, ShuhuiXiao, QiangHuang, LuChen, HailiangTu, RonghuaXu, YongWang, Xuehai
- [39] Optimisation of a series of potent, selective and orally bioavailable GlyT1 inhibitorsBIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (08) : 2235 - 2239Thomson, Joanne L.Blackaby, Wesley P.Jennings, Andrew S. R.Goodacre, Simon C.Pike, AndrewThomas, SteveBrown, Terry A.Smith, AlisonPillai, GopalanStreet, Leslie J.Lewis, Richard T.
- [40] Discovery and optimization of potent, selective, and orally bioavailable Jak1 inhibitorsABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243Zak, MarkJohnson, AdamVan Abbema, AnneWaszkowycz, BohdanEigenbrot, CharlesChang, ChristineHurley, ChristopherHanan, EmilyKenny, JaneKulagowski, JanuszDeVoss, JasonMurray, JeremyBalazs, MercedeszSteffek, MicahKoehler, MichaelGhilardi, NicoChakravarty, ParomaLupardus, PatrickGibbons, PaulDragovich, PeterBergeron, PhilippePulk, RebeccaMendonca, RohanSavage, ScottLabadie, SharadaGradl, StefanWard, StuartBlair, WadeJia, Wei